Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Results of 2023 Annual General Meeting
London, UK, 28 June 2023: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/ Feraccru® (ferric maltol), announces the results of the voting for each of the resolutions as set out in the Notice of Annual General Meeting 2023. The Board reports that resolutions 1 to 10 passed as ordinary resolutions and resolutions 11 and 12 were passed as special resolutions, full details are shown below.
The following table shows the votes cast on each resolution:
|
| VOTES | % | VOTES AGAINST | % | WITHHELD VOTES |
| Resolution 1 | 119,538,439 | 98.78% | 1,475,717 | 1.22% | 77,639 |
| Resolution 2 | 104,595,075 | 86.45% | 16,390,220 | 13.55% | 106,500 |
| Resolution 3 | 119,472,808 | 98.75% | 1,512,487 | 1.25% | 106,500 |
| Resolution 4 | 118,885,249 | 98.26% | 2,100,046 | 1.74% | 106,500 |
| Resolution 5 | 119,959,907 | 99.15% | 1,025,388 | 0.85% | 106,500 |
| Resolution 6 | 120,578,657 | 99.66% | 407,538 | 0.34% | 105,600 |
| Resolution 7 | 119,046,402 | 98.40% | 1,938,893 | 1.60% | 106,500 |
| Resolution 8 | 120,575,411 | 99.64% | 437,845 | 0.36% | 78,539 |
| Resolution 9 | 119,859,760 | 99.06% | 1,143,185 | 0.94% | 88,850 |
| Resolution 10 | 118,585,474 | 97.99% | 2,433,532 | 2.01% | 72,789 |
| Resolution 11 | 117,131,887 | 96.78% | 3,892,308 | 3.22% | 67,600 |
| Resolution 12 | 116,917,813 | 96.61% | 4,106,382 | 3.39% | 67,600 |
Notes:
1. Number of shares in issue 713,036,342.
2. Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/corporate-documents/.
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.
For further information please contact:
| Shield Therapeutics plc | |
| Greg Madison, CEO | +44 (0) 191 511 8500 |
| Hans-Peter Rudolf, CFO |
|
|
Nominated Adviser and Joint Broker |
|
| Peel Hunt LLP |
|
| James Steel/Oliver Duckworth | +44 (0)20 7418 8900 |
|
Joint Broker finnCap Ltd Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks |
+44 (0)20 7220 0500 |
|
|
|
| Financial PR & IR Advisor |
|
| Walbrook PR |
|
| Lianne Applegarth/Alice Woodings | +44 (0)20 7933 8780 or shield@walbrookpr.com |
| |
|
| Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly |
+1 617 429 3548 or jmullaly@lifesciadvisors.com |
About Accrufer®/Feraccru®
Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.